PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 17261957-2 2007 We hypothesized that valsartan, an angiotensin II blocker, attenuates hyperglycemia-induced endothelial dysfunction and downregulates release of proinflammatory cytokines from leukocytes. Valsartan 21-30 angiotensinogen Homo sapiens 35-49 17159079-8 2007 Angiotensin II evoked a significant vasodilatory response only on resistance arteries from patients treated with valsartan, effect blocked by PD123319. Valsartan 113-122 angiotensinogen Homo sapiens 0-14 17146658-9 2007 The ED50 for angiotensin II in the subjects with 1166A/C [95% confidence interval (CI): 4.30 approximately 14.02 ng/kg/min] was significantly lower than in those with 1166A/A (95% CI: 14.23 approximately 28.77 ng/kg/min), while the E(max) for angiotensin II and EC50 for valsartan was similar in both genotype groups. Valsartan 271-280 angiotensinogen Homo sapiens 13-27 17393691-8 2007 In cultured fibroblasts, Ang II stimulation significantly increased DNA synthesis (P < 0.05 vs negative control), which was inhibited by valsartan, an AT1 receptor blocker, but augmented by PD123319, an AT2 receptor antagonist. Valsartan 140-149 angiotensinogen Homo sapiens 25-31 17060512-9 2006 Blockade of endogenous angiotensin II effect by incubation with Valsartan alone inhibited adipogenesis, whereas PD123319 alone promoted adipogenesis, confirming the data using exogenous Ang II. Valsartan 64-73 angiotensinogen Homo sapiens 23-37 16247790-3 2005 This randomized study investigated whether valsartan, a new class of angiotensin II receptor blocker (ARB), can inhibit acute cardiotoxicity after doxorubicin-based chemotherapy. Valsartan 43-52 angiotensinogen Homo sapiens 69-83 16513451-0 2006 The angiotensin II receptor antagonist valsartan inhibits endothelin 1-induced vasoconstriction in the skin microcirculation in humans in vivo: influence of the G-protein beta3 subunit (GNB3) C825T polymorphism. Valsartan 39-48 angiotensinogen Homo sapiens 4-18 15896827-9 2006 These results suggest angiotensin II receptor blockade (valsartan) may be beneficial as an anti-atherosclerotic therapy in patients with type 2 diabetes in addition to its anti-hypertensive action. Valsartan 56-65 angiotensinogen Homo sapiens 22-36 16522324-4 2006 This Ang II-activated PI 3-K/Akt cascade was markedly inhibited by valsartan, an AT(1) receptor-specific blocker, whereas it was enhanced by PD123319, an AT(2) receptor antagonist. Valsartan 67-76 angiotensinogen Homo sapiens 5-11 16522324-6 2006 Moreover, Ang II stimulated tyrosine phosphorylation of EGF receptor and p85alpha subunit of PI 3-K accompanied by an increase in their association, which was inhibited by valsartan, and enhanced by PD123319. Valsartan 172-181 angiotensinogen Homo sapiens 10-16 16522324-7 2006 The Ang II-induced transactivation of EGF receptor resulted in activation of extracellular signal-regulated kinase (ERK) that was also inhibited by valsartan, and enhanced by PD123319. Valsartan 148-157 angiotensinogen Homo sapiens 4-10 16513451-7 2006 RESULTS: Valsartan abolished angiotensin II-induced vasoconstriction and, more importantly, also ET-1-induced vasoconstriction in the skin microcirculation (ET-1 placebo versus valsartan, - 33 +/- 10 PU versus +33 +/- 21 PU for CC [P = .02] and -71 +/- 25 PU versus +108 +/- 21 PU for CT/TT [P < .001]). Valsartan 9-18 angiotensinogen Homo sapiens 29-43 16513451-8 2006 For both ET-1 and angiotensin II, valsartan effects were greater in GNB3 835T-allele carriers (P = .007 and P = .03 for ET-1 and angiotensin II, respectively, for CC versus CT/TT). Valsartan 34-43 angiotensinogen Homo sapiens 18-32 16513451-12 2006 Valsartan inhibited local vasoconstriction to angiotensin II and ET-1 to a greater degree in carriers of the GNB3 825T allele, which adds to data from earlier studies implicating the C825T polymorphism as a pharmacogenetic marker for drug effects. Valsartan 0-9 angiotensinogen Homo sapiens 46-60 15579516-0 2004 Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. Valsartan 137-146 angiotensinogen Homo sapiens 154-168 16042674-0 2005 Angiotensin II receptor blocker-induces blunted taste sensitivity: comparison of candesartan and valsartan. Valsartan 97-106 angiotensinogen Homo sapiens 0-14 16134756-1 2005 Valsartan as angiotensin-II receptor antagonist in normotensive diabetic may provide kidney and heart protection. Valsartan 0-9 angiotensinogen Homo sapiens 13-27 19804097-1 2005 Valsartan (Diovan) is a widely use angiotensin receptor blocker that prevents angiotensin II from binding to the subtype 1 receptor. Valsartan 0-9 angiotensinogen Homo sapiens 78-92 19804097-1 2005 Valsartan (Diovan) is a widely use angiotensin receptor blocker that prevents angiotensin II from binding to the subtype 1 receptor. Valsartan 11-17 angiotensinogen Homo sapiens 78-92 15643130-6 2005 Our data indicate that Ang II increased the expression of gp91phox mRNA in a dose-dependent manner, which was attenuated by Ang II type 1 (AT1) receptor antagonist valsartan. Valsartan 164-173 angiotensinogen Homo sapiens 23-29 15643130-6 2005 Our data indicate that Ang II increased the expression of gp91phox mRNA in a dose-dependent manner, which was attenuated by Ang II type 1 (AT1) receptor antagonist valsartan. Valsartan 164-173 angiotensinogen Homo sapiens 124-130 15643130-7 2005 Similarly, Western blotting revealed that Ang II stimulated an increase in gp91phox, whereas pre-treatment with Valsartan reduced the Ang II-induced expression of gp91phox protein. Valsartan 112-121 angiotensinogen Homo sapiens 134-140 15643130-8 2005 Valsartan as well as superoxide dismutase (SOD) also inhibited Ang II-induced peroxynitrite formation. Valsartan 0-9 angiotensinogen Homo sapiens 63-69 15643130-10 2005 Ang II-induced EPC senescence was significantly inhibited by pre-treatment of either valsartan or SOD (P < 0.01). Valsartan 85-94 angiotensinogen Homo sapiens 0-6 16206603-0 2005 [Combined therapy with quinapril, an ACE inhibitor, and valsartan, a type 1 angiotensin II receptors blocker, for moderate chronic cardiac failure may raise the degree of neurohormonal block and improve 24-h heart rate variability compared to the effect of monotherapy (data from the trial SADKO-CHF)]. Valsartan 56-65 angiotensinogen Homo sapiens 76-90 16206603-1 2005 AIM: To compare effects of various regimens of long-term monotherapy with quinapril (an ACE inhibitor) and valsartan (a type 1 angiotensin II receptors blocker) and combined therapy with these drugs on the activity of heurohormonal systems and 24-h heart rate variability (HRV) in patients with stable moderate chronic cardiac failure (CCF). Valsartan 107-116 angiotensinogen Homo sapiens 127-141 15769395-10 2005 The effect of AngII was blocked by pretreatment of valsartan. Valsartan 51-60 angiotensinogen Homo sapiens 14-19 15579516-8 2004 In conclusion, in mildly sodium-depleted normotensive individuals, the long-lasting effects of aliskiren alone or in combination with valsartan on plasma immunoreactive active renin and urinary aldosterone effects demonstrate strong and prolonged blockade of angiotensin II at the kidney and the adrenal level. Valsartan 134-143 angiotensinogen Homo sapiens 259-273 15000294-6 2004 The maximum increase in blood pressure was completely abolished (118 +/- 3/72 +/- 1 mmHg) when Angiotensin II was infused in volunteers pretreated with valsartan. Valsartan 152-161 angiotensinogen Homo sapiens 95-109 15005273-6 2004 Both the angiotensin type 1 (AT1) receptor antagonist (valsartan: 200 nmol/l) and the PKC inhibitor, bisindolylmaleimide (GFX: 10 micromol/l) reduced Ang II-induced KDR mRNA expression to almost the control level. Valsartan 55-64 angiotensinogen Homo sapiens 150-156 15071355-1 2004 Valsartan selectively blocks angiotensin II binding to the AT1 receptor. Valsartan 0-9 angiotensinogen Homo sapiens 29-43 14747881-1 2004 OBJECTIVE: This prospective, randomised, open-label, blinded-endpoint study was to compare the effects of the angiotensin II (Ang II) AT1 receptor antagonist valsartan with those of the ACE inhibitor enalapril on blood pressure (BP) and cognitive functions in elderly hypertensive patients. Valsartan 158-167 angiotensinogen Homo sapiens 110-124 12970329-0 2003 Angiotensin II receptor blocker valsartan suppresses reactive oxygen species generation in leukocytes, nuclear factor-kappa B, in mononuclear cells of normal subjects: evidence of an antiinflammatory action. Valsartan 32-41 angiotensinogen Homo sapiens 0-14 14761074-1 2003 The present open and prospective study was performed to investigate the effect of the angiotensin II receptor blocker (ARB) valsartan on sexual function in hypertensive males. Valsartan 124-133 angiotensinogen Homo sapiens 86-100 12970329-1 2003 In view of the pro-oxidant and proinflammatory effects of angiotensin II, we have tested the hypothesis that valsartan, an angiotensin receptor blocker, may exert a suppressive action on reactive oxygen species (ROS) generation, nuclear factor kappa B (NF-kappa B) in mononuclear cells. Valsartan 109-118 angiotensinogen Homo sapiens 58-72 12827025-3 2003 In the presence of indomethacin (10 microM) and Nomega-nitro-L-arginine (100 microM), irbesartan, valsartan, and EXP3174 induced a rightward shift of U46619- and angiotensin II-induced contraction. Valsartan 98-107 angiotensinogen Homo sapiens 162-176 12876491-3 2003 Eighteen months later a similar eruption recurred after using valsartan (a competitive inhibitor of angiotensin II receptor). Valsartan 62-71 angiotensinogen Homo sapiens 100-114 12846741-9 2003 Valsartan and PD123319 were used to block the effects of angiotensin II type 1 (AT1) and angiotensin II type 2 (AT2) receptors of angiotensin II, respectively. Valsartan 0-9 angiotensinogen Homo sapiens 57-71 12846741-9 2003 Valsartan and PD123319 were used to block the effects of angiotensin II type 1 (AT1) and angiotensin II type 2 (AT2) receptors of angiotensin II, respectively. Valsartan 0-9 angiotensinogen Homo sapiens 89-103 12846741-9 2003 Valsartan and PD123319 were used to block the effects of angiotensin II type 1 (AT1) and angiotensin II type 2 (AT2) receptors of angiotensin II, respectively. Valsartan 0-9 angiotensinogen Homo sapiens 89-103 12846741-11 2003 Angiotensin II induced TIMP-1, mRNA, and protein expressions in time- and dose-dependent manners, which could be inhibited by the AT1 receptor antagonist valsartan, but not by the AT2 antagonist PD123319. Valsartan 154-163 angiotensinogen Homo sapiens 0-14 12799092-7 2003 The increase in BP after exogenous angiotensin II was completely abolished in volunteers pretreated with valsartan, averaging 118 +/- 3/72 +/- 1 mm Hg by the end of the maximum angiotensin infusion dose. Valsartan 105-114 angiotensinogen Homo sapiens 35-49 12830992-3 2003 The primary objective of VALUE trial is to assess the effect of the angiotensin II (AT1 receptor) antagonist valsartan on the reduction of cardiac morbidity and mortality in patients 50 years of age or older with essential hypertension and a high risk of cardiovascular events. Valsartan 109-118 angiotensinogen Homo sapiens 68-82 12361194-1 2002 The aim of this study was to investigate blood pressure, renal haemodynamics, hormone secretion and the responses to angiotensin II infusion during candesartan cilexetil (candesartan), losartan potassium (losartan) and valsartan treatment in patients with essential hypertension. Valsartan 219-228 angiotensinogen Homo sapiens 117-131 12453539-7 2002 At 1 nM of the AT(1) receptor antagonists, candesartan and valsartan, the maximum contraction was depressed to 57 and 50% of Ang II, respectively, indicating insurmountability. Valsartan 59-68 angiotensinogen Homo sapiens 125-131 12652100-7 2002 The inhibiting effects on the angiotensin II-mediated vasoconstriction by the highest concentration of EXP 3174, valsartan and candesartan did not differ significantly. Valsartan 113-122 angiotensinogen Homo sapiens 30-44 12065072-3 2002 The angiotensin II and III effects are mediated by the angiotensin type 1 receptor as documented by the inhibitory action of valsartan. Valsartan 125-134 angiotensinogen Homo sapiens 4-18 12093312-9 2002 Recent evidence has indicated that the Ang II type 1 receptor antagonist valsartan is of value when used in patients already receiving either an ACE inhibitor or a beta-blocker, but has also suggested that giving all three drugs together is deleterious. Valsartan 73-82 angiotensinogen Homo sapiens 39-45 11967720-10 2002 Multiple linear regression analysis showed that blockade of Ang II induced increase in blood pressure by valsartan contributed to only 30% of the total reduction in Ang II induced rise in PWV (R(2) = 0.306). Valsartan 105-114 angiotensinogen Homo sapiens 60-66 11967720-11 2002 The conclusions were that valsartan completely blocks the effect of Ang II on PWV. Valsartan 26-35 angiotensinogen Homo sapiens 68-74 12361194-8 2002 Candesartan inhibited the angiotensin II induced increase in filtration fraction (0.8 +/- 0.4%) significantly more than losartan (1.5 +/- 0.4%) and valsartan (1.6 +/- 0.4%) and reduced the increase in aldosterone secretion (17 +/- 5 pg/ml/) significantly more than losartan (74 +/- 17 pg/ml/) and valsartan (82 +/- 19 pg/ml/). Valsartan 297-306 angiotensinogen Homo sapiens 26-40 11963637-5 2002 AT1 receptor blockers (losartan, candesartan, irbesartan, valsartan) are available drugs in the angiotensin-II-antagonist class. Valsartan 58-67 angiotensinogen Homo sapiens 96-110 12378864-8 2002 All today available angiotensin II receptor antagonists--losartan, valsartan, irbesartan, candesartan, eprosartan, and telmisartan--equally lower both systolic and diastolic pressure. Valsartan 67-76 angiotensinogen Homo sapiens 20-34 11602816-7 2001 Attenuation of norepinephrine release during exercise by valsartan suggests that angiotensin II facilitates the release of norepinephrine from sympathetic postganglionic neurons. Valsartan 57-66 angiotensinogen Homo sapiens 81-95 11561217-1 2001 Valsartan, a selective antagonist of angiotensin II at the AT(1) receptor subtype, is an efficacious, orally active, blood pressure-lowering agent used in hypertensive patients. Valsartan 0-9 angiotensinogen Homo sapiens 37-51 11561228-3 2001 The level and time course of angiotensin II type 1 (AT(1))-receptor blockade achieved by 160 mg valsartan have not been reported. Valsartan 96-105 angiotensinogen Homo sapiens 29-43 20428262-0 2001 Role of the angiotensin II receptor blocker valsartan in heart failure. Valsartan 44-53 angiotensinogen Homo sapiens 12-26 11881114-0 2001 Valsartan and candesartan can inhibit deteriorating effects of angiotensin II on coronary endothelial function. Valsartan 0-9 angiotensinogen Homo sapiens 63-77 11244025-0 2001 Effect of valsartan on angiotensin II-induced plasminogen activator inhibitor-1 biosynthesis in arterial smooth muscle cells. Valsartan 10-19 angiotensinogen Homo sapiens 23-37 11244025-4 2001 The angiotensin II-induced plasminogen activator inhibitor activity was inhibited, in a concentration-dependent manner, by valsartan with an IC(50) value of 21 nmol/L. Valsartan 123-132 angiotensinogen Homo sapiens 4-18 11244025-5 2001 Valsartan fully prevented the angiotensin II-induced increase in plasminogen activator inhibitor-1 protein and mRNA. Valsartan 0-9 angiotensinogen Homo sapiens 30-44 11244025-8 2001 Thus, valsartan effectively inhibits angiotensin II-induced plasminogen activator inhibitor-1 secretion without affecting that of tissue plasminogen activator in arterial rat and human smooth muscle cells. Valsartan 6-15 angiotensinogen Homo sapiens 37-51 11206708-0 2000 Interaction between the partially insurmountable antagonist valsartan and human recombinant angiotensin II type 1 receptors. Valsartan 60-69 angiotensinogen Homo sapiens 92-106 11206708-3 2000 It was inhibited by other AT1 receptor antagonists with the same potency order as previously described for the binding of [3H]-angiotensin II and [3H]-candesartan to human AT1 receptors (i.e. candesartan > or = EXP3174 > valsartan = irbesartan = angiotensin II > losartan). Valsartan 227-236 angiotensinogen Homo sapiens 127-141 11206708-6 2000 Hence, valsartan interacts with the AT1 receptor in a manner that is competitive with angiotensin II. Valsartan 7-16 angiotensinogen Homo sapiens 86-100 11206708-10 2000 In agreement, pre-incubation of the CHO-AT1 cells with 5 and 50 nM valsartan produced a partial inhibition of the angiotensin II induced increase of the free intracellular calcium concentration. Valsartan 67-76 angiotensinogen Homo sapiens 114-128 11206708-12 2000 In functional recovery experiments with valsartan-pre-treated cells, the angiotensin II-mediated response was half-maximally restored within approximately 30 min. Valsartan 40-49 angiotensinogen Homo sapiens 73-87 11131281-0 2000 Effects of valsartan on angiotensin II-induced migration of human coronary artery smooth muscle cells. Valsartan 11-20 angiotensinogen Homo sapiens 24-38 11131281-2 2000 In the current study, we examined the effects of the angiotensin type 1 receptor antagonist valsartan on angiotensin II (Ang II)-induced migration of cultured human coronary artery SMC using Boyden"s chamber methods. Valsartan 92-101 angiotensinogen Homo sapiens 105-119 11131281-2 2000 In the current study, we examined the effects of the angiotensin type 1 receptor antagonist valsartan on angiotensin II (Ang II)-induced migration of cultured human coronary artery SMC using Boyden"s chamber methods. Valsartan 92-101 angiotensinogen Homo sapiens 121-127 11131281-5 2000 Ang II-induced migration was blocked by the Ang II type 1 (AT1) receptor antagonist valsartan in a concentration-dependent manner. Valsartan 84-93 angiotensinogen Homo sapiens 0-6 11131281-5 2000 Ang II-induced migration was blocked by the Ang II type 1 (AT1) receptor antagonist valsartan in a concentration-dependent manner. Valsartan 84-93 angiotensinogen Homo sapiens 44-50 11131281-10 2000 Valsartan may prevent the progression of coronary atherosclerosis through an inhibition of Ang II-induced migration and proliferation in these cells, although in vivo evidence is lacking. Valsartan 0-9 angiotensinogen Homo sapiens 91-97 11206708-1 2000 The interaction between the AT1 receptor-selective antagonist valsartan, and its human receptor, was investigated by direct radioligand binding as well as by its inhibition of angiotensin II induced inositol phosphate accumulation in CHO cells expressing human recombinant AT1 receptors. Valsartan 62-71 angiotensinogen Homo sapiens 176-190 17199210-0 2000 New basic science initiatives with the angiotensin II receptor blocker valsartan. Valsartan 71-80 angiotensinogen Homo sapiens 39-53 17199210-2 2000 Valsartan is a highly selective Ang II receptor blocker that specifically and selectively blocks Ang II at the AT1-receptor. Valsartan 0-9 angiotensinogen Homo sapiens 32-38 17199210-2 2000 Valsartan is a highly selective Ang II receptor blocker that specifically and selectively blocks Ang II at the AT1-receptor. Valsartan 0-9 angiotensinogen Homo sapiens 97-103 17199217-5 2000 Complete blockade of angiotensin II (Ang II) action with the highly selective Ang II receptor blocker (ARB) valsartan, both as monotherapy and in combination with ACE inhibitors, is well-tolerated and efficacious in patients with renal failure. Valsartan 108-117 angiotensinogen Homo sapiens 21-35 17199217-5 2000 Complete blockade of angiotensin II (Ang II) action with the highly selective Ang II receptor blocker (ARB) valsartan, both as monotherapy and in combination with ACE inhibitors, is well-tolerated and efficacious in patients with renal failure. Valsartan 108-117 angiotensinogen Homo sapiens 37-43 17199217-5 2000 Complete blockade of angiotensin II (Ang II) action with the highly selective Ang II receptor blocker (ARB) valsartan, both as monotherapy and in combination with ACE inhibitors, is well-tolerated and efficacious in patients with renal failure. Valsartan 108-117 angiotensinogen Homo sapiens 78-84 10981149-7 2000 In addition, it is now apparent that the therapeutic reduction in BP with AT1 receptor blockade (eg, losartan, valsartan, candesartan) is mediated by ANG II stimulation of the AT2 receptor, leading to increased levels of BK, NO, and cGMP. Valsartan 111-120 angiotensinogen Homo sapiens 150-156 12555316-1 2000 Valsartan, an angiotensin II antagonist with a potent and highly selective effect on AT1 receptors, has been found effective and safe in several randomized, controlled studies versus a placebo, other antihypertensive agents, or other angiotensin II antagonists. Valsartan 0-9 angiotensinogen Homo sapiens 14-28 12555316-1 2000 Valsartan, an angiotensin II antagonist with a potent and highly selective effect on AT1 receptors, has been found effective and safe in several randomized, controlled studies versus a placebo, other antihypertensive agents, or other angiotensin II antagonists. Valsartan 0-9 angiotensinogen Homo sapiens 234-248 10587770-2 1999 Valsartan (Diovan) is an antihypertensive drug belonging to the family of angiotensin II receptor antagonists. Valsartan 0-9 angiotensinogen Homo sapiens 74-88 11019424-1 2000 AIM: To assess effectiveness of diovan, a novel angiotensin-II antagonist, in combined hypotensive treatment of patients with severe arterial hypertension. Valsartan 32-38 angiotensinogen Homo sapiens 48-62 10588088-1 1999 Several angiotensin II receptor blockers (ARBs), including candesartan cilexetil, irbesartan, losartan, telmisartan, and valsartan, are currently approved by the US Food and Drug Administration (FDA) for the treatment of patients with hypertension. Valsartan 121-130 angiotensinogen Homo sapiens 8-22 10587770-2 1999 Valsartan (Diovan) is an antihypertensive drug belonging to the family of angiotensin II receptor antagonists. Valsartan 11-17 angiotensinogen Homo sapiens 74-88 10442512-0 1999 Valsartan inhibits angiotensin II-stimulated proliferation of smooth muscle cells from human coronary artery. Valsartan 0-9 angiotensinogen Homo sapiens 19-33 10546920-0 1999 Time course and extent of angiotensin II antagonism after irbesartan, losartan, and valsartan in humans assessed by angiotensin II dose response and radioligand receptor assay. Valsartan 84-93 angiotensinogen Homo sapiens 26-40 10442512-3 1999 METHOD: The effect of valsartan on the angiotensin II-stimulated proliferation of smooth muscle cells from human coronary artery was investigated. Valsartan 22-31 angiotensinogen Homo sapiens 39-53 10442512-4 1999 RESULTS: Angiotensin II significantly increased cell proliferation by about 30% at a concentration of 10(-6) M without significant changes at the lower concentrations 10(-7) and 10(-8) M. Valsartan at the dosages 10(-8) to 10(-6) M had no effect on serum-stimulated proliferation. Valsartan 188-197 angiotensinogen Homo sapiens 9-23 10232502-0 1999 A comparison of the angiotensin II antagonists valsartan and losartan in the treatment of essential hypertension. Valsartan 47-56 angiotensinogen Homo sapiens 20-34 10028951-0 1999 Angiotensin II antagonism in clinical practice: experience with valsartan. Valsartan 64-73 angiotensinogen Homo sapiens 0-14 10449888-0 1999 Angiotensin II antagonism and the heart: valsartan in left ventricular hypertrophy. Valsartan 41-50 angiotensinogen Homo sapiens 0-14 10449888-2 1999 In a randomized, double-blind study the angiotensin II (AT(1) receptor) antagonist valsartan (Diovan((R)); 80 mg/160 mg q.d.) Valsartan 83-92 angiotensinogen Homo sapiens 40-70 10449890-1 1999 Valsartan is a specific angiotensin II receptor antagonist with high selectivity for the AT(1) receptor subtype. Valsartan 0-9 angiotensinogen Homo sapiens 24-38 10449890-2 1999 After oral administration of single or repeated once-daily doses, valsartan 40-80 mg inhibits the pressor response to angiotensin II for 24 hours. Valsartan 66-75 angiotensinogen Homo sapiens 118-132 10028952-0 1999 Angiotensin II antagonism and the heart: valsartan in left ventricular hypertrophy. Valsartan 41-50 angiotensinogen Homo sapiens 0-14 10234113-0 1997 Valsartan, a new angiotensin II antagonist; blood pressure reduction in essential hypertension compared with an angiotensin converting enzyme inhibitor, enalapril. Valsartan 0-9 angiotensinogen Homo sapiens 17-31 10358862-1 1999 AIM: To study clinical effectiveness and tolerance of diovan, a new angiotensin-II antagonist, in patients with mild and moderate blood hypertension (BH). Valsartan 54-60 angiotensinogen Homo sapiens 68-82 9761285-8 1998 The AT1 antagonist CGP48933 (10(-8) to 10(-12) M), but not the AT2 antagonist CGP42112 (10(-8) to 10(-12) M), inhibited AII (10(-8) M)-induced proliferation and migration in a concentration-dependent manner (P < 0.05). Valsartan 19-27 angiotensinogen Homo sapiens 120-123 9570479-3 1998 Using the highly selective angiotensin II AT1 receptor antagonist valsartan, a concentration-dependent inhibition of angiotensin II-induced SAPK activity is observed, clearly implying the AT1-receptor in this angiotensin II-mediated response. Valsartan 66-75 angiotensinogen Homo sapiens 27-41 9570479-3 1998 Using the highly selective angiotensin II AT1 receptor antagonist valsartan, a concentration-dependent inhibition of angiotensin II-induced SAPK activity is observed, clearly implying the AT1-receptor in this angiotensin II-mediated response. Valsartan 66-75 angiotensinogen Homo sapiens 117-131 9570479-3 1998 Using the highly selective angiotensin II AT1 receptor antagonist valsartan, a concentration-dependent inhibition of angiotensin II-induced SAPK activity is observed, clearly implying the AT1-receptor in this angiotensin II-mediated response. Valsartan 66-75 angiotensinogen Homo sapiens 117-131 9257084-2 1997 Valsartan competitively and selectively inhibits the actions of angiotensin II at the AT1 receptor subtype which is responsible for most of the known effects of angiotensin II. Valsartan 0-9 angiotensinogen Homo sapiens 64-78 9257084-2 1997 Valsartan competitively and selectively inhibits the actions of angiotensin II at the AT1 receptor subtype which is responsible for most of the known effects of angiotensin II. Valsartan 0-9 angiotensinogen Homo sapiens 161-175 10463202-0 1999 Treatment with the angiotensin II antagonist valsartan in patients with chronic renal failure and hypertension. Valsartan 45-54 angiotensinogen Homo sapiens 19-33 9848776-0 1998 Effects of the angiotensin II antagonist valsartan on blood pressure, proteinuria, and renal hemodynamics in patients with chronic renal failure and hypertension. Valsartan 41-50 angiotensinogen Homo sapiens 15-29 9853274-2 1998 The purpose of the present study was to investigate the acute and sustained effects of indomethacin on the renal response to the angiotensin II receptor antagonist valsartan and to the ACE inhibitor enalapril. Valsartan 164-173 angiotensinogen Homo sapiens 129-143 9808602-11 1998 CONCLUSIONS: Antihypertensive treatment with the angiotensin II antagonist valsartan for 8 months produced a significant regression of LVH in predominantly previously untreated patients with essential hypertension. Valsartan 75-84 angiotensinogen Homo sapiens 49-63 15991938-0 1998 Pharmacology of valsartan, an angiotensin II receptor antagonist. Valsartan 16-25 angiotensinogen Homo sapiens 30-44 15991938-1 1998 Valsartan is the second orally-active, non-peptide angiotensin II receptor blocker to reach the market in Europe and the USA for the treatment of hypertension. Valsartan 0-9 angiotensinogen Homo sapiens 51-65 15991938-3 1998 Experimentally, valsartan dose-dependently inhibits the vasoconstriction induced by angiotensin II and lowers blood pressure in renin-dependent models of hypertension. Valsartan 16-25 angiotensinogen Homo sapiens 84-98 9551704-0 1998 An interaction study with cimetidine and the new angiotensin II antagonist valsartan. Valsartan 75-84 angiotensinogen Homo sapiens 49-63 9421693-8 1997 In terms of UAE reduction, better results are obtained with ACE inhibitors or angiotensin II antagonists such as losartan and valsartan, than with other antihypertensive classes, although their true impact in preserving renal function needs to be assessed. Valsartan 126-135 angiotensinogen Homo sapiens 78-92 9333102-1 1997 OBJECTIVES: Valsartan (CGP 48933), an orally active angiotensin II antagonist, is eliminated mainly by hepatic clearance. Valsartan 12-21 angiotensinogen Homo sapiens 52-66 9322828-0 1997 Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril. Valsartan 0-9 angiotensinogen Homo sapiens 17-31 10234113-1 1997 OBJECTIVE: To compare the blood pressure reduction induced by valsartan, a new angiotensin II receptor antagonist, with that induced by enalapril, an angiotensin converting enzyme (ACE) inhibitor in essential hypertension. Valsartan 62-71 angiotensinogen Homo sapiens 79-93 9024172-0 1997 The effect of valsartan on the angiotensin II pressor response in healthy normotensive male subjects. Valsartan 14-23 angiotensinogen Homo sapiens 31-45 9220209-0 1997 Valsartan, a new angiotensin II antagonist: antihypertensive effects over 24 hours. Valsartan 0-9 angiotensinogen Homo sapiens 17-31 9024172-1 1997 OBJECTIVE: Valsartan is an oral antagonist of angiotensin II that competes with angiotensin II for the AT1-receptor and is being developed as an antihypertensive agent. Valsartan 11-20 angiotensinogen Homo sapiens 46-60 9024172-1 1997 OBJECTIVE: Valsartan is an oral antagonist of angiotensin II that competes with angiotensin II for the AT1-receptor and is being developed as an antihypertensive agent. Valsartan 11-20 angiotensinogen Homo sapiens 80-94 9024172-2 1997 This study assessed the ability of 80 mg valsartan to inhibit the pressor effect of exogenous angiotensin II in healthy normotensive men, first after a single dose and then after multiple doses once daily for 7 days. Valsartan 41-50 angiotensinogen Homo sapiens 94-108 9024172-7 1997 RESULTS: Systolic blood pressure responses to angiotensin II challenges after single and multiple doses of valsartan were significantly lower than placebo, indicating that valsartan blocked the blood pressure response to angiotensin II. Valsartan 172-181 angiotensinogen Homo sapiens 46-60 9218922-0 1997 Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared to hydrochlorothiazide. Valsartan 0-9 angiotensinogen Homo sapiens 17-31 9218922-1 1997 OBJECTIVE: To compare the antihypertensive efficacy of a new angiotensin II antagonist, valsartan, with a reference therapy, hydrochlorothiazide (HCTZ). Valsartan 88-97 angiotensinogen Homo sapiens 61-75 9342579-0 1997 Pharmacokinetics and pharmacodynamic effects of the angiotensin II antagonist valsartan at steady state in healthy, normotensive subjects. Valsartan 78-87 angiotensinogen Homo sapiens 52-66 9342579-13 1997 Indirect evidence of AT1 blockade by valsartan is demonstrated by an increase of plasma Ang II and by a blunted DBP response to passive tilting. Valsartan 37-46 angiotensinogen Homo sapiens 88-94 9024172-7 1997 RESULTS: Systolic blood pressure responses to angiotensin II challenges after single and multiple doses of valsartan were significantly lower than placebo, indicating that valsartan blocked the blood pressure response to angiotensin II. Valsartan 172-181 angiotensinogen Homo sapiens 221-235 9024172-10 1997 The angiotensin II blocking effect was maintained up to this time, despite low plasma valsartan levels and minimal accumulation after multiple doses. Valsartan 86-95 angiotensinogen Homo sapiens 4-18 9024172-11 1997 CONCLUSION: Valsartan, 80 mg, is a potent angiotensin II antagonist with a rapid onset of action and persistent angiotensin II inhibition up to 24 hours. Valsartan 12-21 angiotensinogen Homo sapiens 42-56 9024172-11 1997 CONCLUSION: Valsartan, 80 mg, is a potent angiotensin II antagonist with a rapid onset of action and persistent angiotensin II inhibition up to 24 hours. Valsartan 12-21 angiotensinogen Homo sapiens 112-126 8841157-0 1996 Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine. Valsartan 0-9 angiotensinogen Homo sapiens 17-31 8841157-1 1996 OBJECTIVE: To compare the antihypertensive efficacy of a new angiotensin II antagonist, valsartan, with a reference therapy, amlodipine. Valsartan 88-97 angiotensinogen Homo sapiens 61-75 7867676-0 1994 Angiotensin II receptor blockade with single doses of valsartan in healthy, normotensive subjects. Valsartan 54-63 angiotensinogen Homo sapiens 0-14 8986917-0 1996 Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril. Valsartan 0-9 angiotensinogen Homo sapiens 17-31 8986917-1 1996 OBJECTIVE: To compare the antihypertensive efficacy and systemic tolerability of valsartan, a new angiotensin II receptor antagonist, with placebo and with an angiotensin converting enzyme (ACE) inhibitor, enalapril. Valsartan 81-90 angiotensinogen Homo sapiens 98-112 7980530-8 1994 The effects of AI were reduced by the ACE inhibitor benazeprilat, while those of AII were prevented by valsartan, an AT1 antagonist. Valsartan 103-112 angiotensinogen Homo sapiens 81-84 7867676-1 1994 Valsartan (CGP 48933), a specific blocker of the angiotensin II (Ang II) receptor subtype 1 (AT1 receptor) was administered in single, oral doses of 40 mg and 80 mg to six healthy, normotensive male volunteers in a double-blind, placebo-controlled, randomized crossover trial. Valsartan 0-9 angiotensinogen Homo sapiens 49-63 34282597-6 2021 PA diagnosis was based on a combined screening-diagnostic overnight test, the Dexamethasone-Captopril-Valsartan Test (DCVT) that evaluates aldosterone secretion after pharmaceutical blockade of angiotensin-II and adrenocorticotropic hormone. Valsartan 102-111 angiotensinogen Homo sapiens 194-240 34453839-5 2021 KEY FINDINGS: Our data revealed that pretreatment with nebivolol and nebivolol/valsartan combination significantly reduced ANG II-induced oxidative stress and mTORC1 signalling. Valsartan 79-88 angiotensinogen Homo sapiens 123-129 34453839-6 2021 Concurrently, ANG II-induced activation of inflammatory cytokines and fetal gene expressions were significantly suppressed by nebivolol and nebivolol/valsartan combination. Valsartan 150-159 angiotensinogen Homo sapiens 14-20 34453839-7 2021 Pretreatment with nebivolol and nebivolol/valsartan combination alleviated ANG II-induced impairment of mitochondrial biogenesis by restoring the gene expression levels of PGC-1alpha, TFAM, NRF-1 and SIRT3. Valsartan 42-51 angiotensinogen Homo sapiens 75-81 34453839-9 2021 SUMMARY: These findings suggest that both nebivolol and nebivolol/valsartan combination exert protective effects on ANG II-induced mitochondrial dysfunction by alleviating its biogenesis and dynamics. Valsartan 66-75 angiotensinogen Homo sapiens 116-122 35598697-10 2022 Sacubitril works synergistically with valsartan by inhibiting the degradation of angiotensin II, thereby increasing its bioavailability. Valsartan 38-47 angiotensinogen Homo sapiens 81-95 33489085-8 2020 Sacubitril/valsartan concomitantly blocks the renin-angiotensin system and inhibits neprilysin, a ubiquitous enzyme responsible for the breakdown of more than 50 vasoactive peptides, including the biologically active natriuretic peptides, bradykinin, angiotensin I and II, endothelin 1, glucagon, glucagon-like peptide-1, insulin-B chain, and others. Valsartan 11-20 angiotensinogen Homo sapiens 251-271 28400916-8 2017 Although all agents are very potent inhibitors of G protein activation at the AT1R, candesartan and valsartan were uncovered to be the most potent ARBs at blocking betaarr activation by AngII and at suppressing aldosterone in vitro and in vivo in post-myocardial infarction HF animals. Valsartan 100-109 angiotensinogen Homo sapiens 186-191 31803758-5 2019 The antihypertensive effect of valsartan after 14-day treatment was associated with reduced left ventricular wall thickness and augmented plasma concentrations of angiotensin I (Ang I) and Ang II; rat and human concentrations of angiotensinogen or Ang-(1-12) did not change. Valsartan 31-40 angiotensinogen Homo sapiens 229-244 30536556-9 2019 Valsartan attenuated all the effects we described after exposure to Ang II but not those observed after UA exposure. Valsartan 0-9 angiotensinogen Homo sapiens 68-74 30998981-6 2019 Ang II significantly increased the macroscopic BKCa currents at the whole cell level, while increased the open probability and decreased the mean close time of BKCa channels at the single channel level with AT1R blockade by valsartan in NP. Valsartan 224-233 angiotensinogen Homo sapiens 0-6 30776409-6 2019 Ang II-induced senescent progression and inflammation were attenuated by angiotensin receptor blocker valsartan. Valsartan 102-111 angiotensinogen Homo sapiens 0-6 30776409-7 2019 In young PDL5 cells, Ang II promoted the endothelial viability including cell proliferation, migration, angiogenesis and cell adhesion to monocytes; however, chronic stimulation of Ang II suppressed the cell viability, promoted cell adhesion and apoptosis in senescent PDL25 cells, which could be ameliorated by short-term valsartan, but long-term valsartan had no effects. Valsartan 323-332 angiotensinogen Homo sapiens 21-27 30776409-7 2019 In young PDL5 cells, Ang II promoted the endothelial viability including cell proliferation, migration, angiogenesis and cell adhesion to monocytes; however, chronic stimulation of Ang II suppressed the cell viability, promoted cell adhesion and apoptosis in senescent PDL25 cells, which could be ameliorated by short-term valsartan, but long-term valsartan had no effects. Valsartan 323-332 angiotensinogen Homo sapiens 181-187 30776409-7 2019 In young PDL5 cells, Ang II promoted the endothelial viability including cell proliferation, migration, angiogenesis and cell adhesion to monocytes; however, chronic stimulation of Ang II suppressed the cell viability, promoted cell adhesion and apoptosis in senescent PDL25 cells, which could be ameliorated by short-term valsartan, but long-term valsartan had no effects. Valsartan 348-357 angiotensinogen Homo sapiens 21-27 30776409-7 2019 In young PDL5 cells, Ang II promoted the endothelial viability including cell proliferation, migration, angiogenesis and cell adhesion to monocytes; however, chronic stimulation of Ang II suppressed the cell viability, promoted cell adhesion and apoptosis in senescent PDL25 cells, which could be ameliorated by short-term valsartan, but long-term valsartan had no effects. Valsartan 348-357 angiotensinogen Homo sapiens 181-187 30212210-3 2018 To prevent hypertension, nonpeptide "sartan" drugs, such as valsartan (VST), have been developed to competitively block the access of angiotensin II to the receptor. Valsartan 60-69 angiotensinogen Homo sapiens 134-148 30212210-3 2018 To prevent hypertension, nonpeptide "sartan" drugs, such as valsartan (VST), have been developed to competitively block the access of angiotensin II to the receptor. Valsartan 71-74 angiotensinogen Homo sapiens 134-148 28587583-2 2017 With the simultaneous blockage of the enzyme neprilysin (by sacubitril) and angiotensin II receptors (by valsartan), this combination reduces the degradation of natriuretic peptides and other counterregulatory peptide systems while avoiding the deleterious effect of angiotensin II receptors activation and thereby encompasses a beneficial impact of 2 important neurohormonal pathways activated in heart failure. Valsartan 105-114 angiotensinogen Homo sapiens 76-90 28587583-2 2017 With the simultaneous blockage of the enzyme neprilysin (by sacubitril) and angiotensin II receptors (by valsartan), this combination reduces the degradation of natriuretic peptides and other counterregulatory peptide systems while avoiding the deleterious effect of angiotensin II receptors activation and thereby encompasses a beneficial impact of 2 important neurohormonal pathways activated in heart failure. Valsartan 105-114 angiotensinogen Homo sapiens 267-281 26995372-0 2016 Effect of Angiotensin II Type I Receptor Blockade with Valsartan on Carotid Artery Atherosclerosis: A Double Blind Randomized Clinical Trial Comparing Valsartan and Placebo (EFFERVESCENT). Valsartan 55-64 angiotensinogen Homo sapiens 10-24 28338173-2 2017 Many studies indicated that valsartan can also increase angiotensin II, andosterone and plasma renin activity (PRA). Valsartan 28-37 angiotensinogen Homo sapiens 56-70 28133468-3 2016 It is described as the first in class angiotensin receptor neprilysin inhibitor (ARNI) since it incorporates the neprilysin inhibitor, sacubitril and the angiotensin II receptor antagonist, valsartan. Valsartan 190-199 angiotensinogen Homo sapiens 154-168 28387384-1 2017 Clinical trials demonstrated that a fixed-dose combination (FDC) of the beta-blocker nebivolol (5 mg) and the angiotensin II antagonist valsartan (80 mg) produced a significant reduction of both diastolic and systolic blood pressure in patients with hypertension. Valsartan 136-145 angiotensinogen Homo sapiens 110-124 26197716-7 2016 The Wnt/beta-catenin signaling ligand, Wnt3a, was not expressed in the control or Val-treated groups, whereas in Ang II-treated cells, both Wnt3a and beta-catenin gene expression were enhanced (P < 0.01).The effect of Ang II can be inhibited by the addition of Val (P < 0.05). Valsartan 264-267 angiotensinogen Homo sapiens 113-119 26873036-3 2016 Valsartan counterbalances the increase of angiotensin II that results from neprilysin inhibition, exerting also the beneficial effects of angiotensin receptor blockers seen in previous HF trials. Valsartan 0-9 angiotensinogen Homo sapiens 42-56 26466607-3 2015 LCZ696 (sacubitril/valsartan) is an angiotensin-receptor neprilysin inhibitor recently approved for HFrEF, with dual actions that result in enhancement of natriuretic peptide levels and blockade of angiotensin II activities. Valsartan 19-28 angiotensinogen Homo sapiens 198-212 22392065-0 2012 Valsartan and telmisartan abrogate angiotensin II-induced downregulation of ABCA1 expression via AT1 receptor, rather than AT2 receptor or PPARgamma activation. Valsartan 0-9 angiotensinogen Homo sapiens 35-49 25631300-4 2015 However, candesartan and valsartan were the most potent at blocking AngII-induced betaarr activation at this receptor, among the tetrazolo-biphenyl-methyl derivatives, translating into excellent efficacies at aldosterone suppression in H295R cells. Valsartan 25-34 angiotensinogen Homo sapiens 68-73 24420549-3 2014 In a balanced crossover design, men (n=8) and women (n=8) were intranasally administered ANGII (400 mug) or placebo after ANGII type 1 receptors had been blocked by pretreatment with valsartan (80 mg; 12 and 6 hours before intranasal administration). Valsartan 183-192 angiotensinogen Homo sapiens 89-94 24070321-7 2013 EXPERT OPINION: Azilsartan medoxomil has a potent and persistent ability to inhibit binding of angiotensin II to AT1 receptors, which may play a role in its superior blood pressure (BP) -lowering efficacy compared with other drugs, including ramipril, candesartan, valsartan or olmesartan, without an increase of side effects. Valsartan 265-274 angiotensinogen Homo sapiens 95-109 27122680-0 2013 Effect of 8-Week Combination Therapy with an Extended-Release alpha1-Blocker (Bunazosin or Doxazosin) in Inadequate Responders to an Angiotensin II Antagonist (Valsartan) in Patients with Stage 1 or 2 Essential Hypertension. Valsartan 160-169 angiotensinogen Homo sapiens 133-147 25853236-2 2015 The aims of this phase I study were to investigate pharmacokinetic and pharmacodynamic interactions between nebivolol, a vasodilatory beta1-selective blocker, and valsartan, an angiotensin II receptor blocker, and to assess safety and tolerability of the combination. Valsartan 163-172 angiotensinogen Homo sapiens 177-191 25853236-10 2015 A sharp increase in mean day 7 plasma renin activity and plasma angiotensin II that occurred in valsartan-treated participants was significantly attenuated with concomitant nebivolol administration. Valsartan 96-105 angiotensinogen Homo sapiens 64-78 25747524-2 2015 Valsartan is highly selective angiotensin AT1 receptor blocker and exerts its major pharmacological effect by decreasing angiotensin II-induced vasoconstriction and production of aldosterone. Valsartan 0-9 angiotensinogen Homo sapiens 121-135 25591555-10 2015 Relative expression of COX-2 and secretion of TXB 2 with concordant phosphorylation of p38MAPK and NF-kB were increased in HAECs when stimulated by Ang II (100 nmol/L) but were significantly decreased by valsartan pretreatment (100 nmol/L). Valsartan 204-213 angiotensinogen Homo sapiens 148-154 25025993-10 2014 These effects were similar to that of angiotensin II and could be weakened partly by the AT1-receptor blocker valsartan. Valsartan 110-119 angiotensinogen Homo sapiens 38-52 24219285-9 2013 Additionally, these Ang II-mediated reductions could be attenuated by AT1R antagonist valsartan. Valsartan 86-95 angiotensinogen Homo sapiens 20-26 22967656-13 2012 Several pharmaceuticals were detected in the Spanish samples, where irbesartan and valsartan - two Angiotensin II antagonists that are not commonly monitored in the aquatic environment - were the compounds most frequently detected. Valsartan 83-92 angiotensinogen Homo sapiens 99-113 22392065-1 2012 The possible pharmacological mechanism by which partial PPARgamma-activating angiotensin II (Ang II) type 1 receptor blocker (ARB) telmisartan and non-PPARgamma-activating ARB valsartan reverse Ang II-suppressed ABCA1 expression is still unclear. Valsartan 176-185 angiotensinogen Homo sapiens 194-200 22392065-6 2012 Valsartan and telmisartan could both reverse the downregulation of Ang II on ABCA1 expression. Valsartan 0-9 angiotensinogen Homo sapiens 67-73 22392065-9 2012 Both valsartan and telmisartan abrogate Ang II-induced downregulation of ABCA1 expression mainly through AT1 receptor rather than through AT2 receptor or PPARgamma-dependent pathway. Valsartan 5-14 angiotensinogen Homo sapiens 40-46 20664555-0 2011 Angiotensin II receptor blockade with valsartan decreases plasma osteopontin levels in patients with essential hypertension. Valsartan 38-47 angiotensinogen Homo sapiens 0-14 22282241-0 2012 Valsartan inhibits angiotensin II-induced proliferation of vascular smooth muscle cells via regulating the expression of mitofusin 2. Valsartan 0-9 angiotensinogen Homo sapiens 19-33 22282241-2 2012 In our study, we observed the effects of valsartan on proliferation of cultured VSMCs treated with or without ANGII by cell counting and methyl thiazolyl tetrazolium (MTT) assay, and detected the expression of mitofusin 2 (Mfn2), a newly discovered cell proliferation inhibitor and a related cell proliferation signaling pathway protein by Western blotting. Valsartan 41-50 angiotensinogen Homo sapiens 110-115 22282241-4 2012 Valsartan inhibited such effects of ANGII at concentrations of 10(-5) and 10(-6) mol/L, but not at 10(-7) mol/L. Valsartan 0-9 angiotensinogen Homo sapiens 36-41 22282241-6 2012 These results suggest that valsartan inhibits ANGII-induced proliferation of VSMCs in vitro via Mfn2-Ras-Raf-ERK/MAPK signaling pathway. Valsartan 27-36 angiotensinogen Homo sapiens 46-51 21324549-1 2011 We report the rare case of angioedema (also known as Quincke edema), which was induced by valsartan, an angiotensin II receptor blocker (ARB). Valsartan 90-99 angiotensinogen Homo sapiens 104-118 20664555-3 2011 The aim of this study was to clarify the effect of angiotensin II receptor blockade with valsartan on plasma OPN levels in patients with essential hypertension (EHT). Valsartan 89-98 angiotensinogen Homo sapiens 51-65 20615910-9 2011 In patients with IgA nephropathy, treatment with an ARB, valsartan (40 mg/day), significantly increased renal plasma flow and decreased filtration fraction, which were associated with reductions in urinary angiotensinogen levels. Valsartan 57-66 angiotensinogen Homo sapiens 206-221 20504911-0 2010 Contribution of bradykinin B2 receptors to the inhibition by valsartan of systemic and renal effects of exogenous angiotensin II in salt-repleted humans. Valsartan 61-70 angiotensinogen Homo sapiens 114-128 21095266-5 2010 CONCLUSION: This large prospective, double-blind, randomized, placebo-controlled trial will establish the role of angiotensin II receptor blockers (valsartan) in the treatment of patients with a systemic right ventricle. Valsartan 148-157 angiotensinogen Homo sapiens 114-128 18633763-0 2008 Long-term effects of angiotensin II receptor blockade with valsartan on carotid arterial stiffness and hemodynamic alterations in patients with essential hypertension. Valsartan 59-68 angiotensinogen Homo sapiens 21-35 20463030-7 2010 Ang-II application to cardiomyocyte nuclei enhanced NFkappaB mRNA expression, a response that was suppressed by co-administration of AT1R (valsartan) and/or AT2R (PD123177) blockers. Valsartan 139-148 angiotensinogen Homo sapiens 0-6 20329655-1 2010 Valsartan (CAS 137862-53-4) is an antihypertensive drug belonging to the family of angiotensin II receptor antagonists acting at the AT1 receptor, which mediates all known effects of angiotensin II on the cardiovascular system. Valsartan 0-9 angiotensinogen Homo sapiens 83-97 20329655-1 2010 Valsartan (CAS 137862-53-4) is an antihypertensive drug belonging to the family of angiotensin II receptor antagonists acting at the AT1 receptor, which mediates all known effects of angiotensin II on the cardiovascular system. Valsartan 0-9 angiotensinogen Homo sapiens 183-197 19749478-0 2009 Angiotensin II receptor blocker, valsartan, increases myocardial blood volume and regresses hypertrophy in hypertensive patients. Valsartan 33-42 angiotensinogen Homo sapiens 0-14 19749478-8 2009 CONCLUSIONS: Valsartan, an angiotensin II receptor blocker, corrected the decreased MBV in association with regression of LVH in patients with HT. Valsartan 13-22 angiotensinogen Homo sapiens 27-41 19417110-3 2009 OBJECTIVE: To investigate the effects of ACE inhibitors versus valsartan on the angiotensin II signal transduction pathways in the transplanted human heart. Valsartan 63-72 angiotensinogen Homo sapiens 80-94 19225232-7 2009 AIM: The aim of this project was to (i) identify a repertoire of proinflammatory mesangial cell AII-inducible mRNAs; (ii) determine if the AII-induced proinflammatory mRNA responses depend on ambient glucose, and (iii) test the anti-inflammatory effectiveness of an ARB, valsartan, either alone or in combination with a statin, simvastatin. Valsartan 271-280 angiotensinogen Homo sapiens 96-99 19225232-7 2009 AIM: The aim of this project was to (i) identify a repertoire of proinflammatory mesangial cell AII-inducible mRNAs; (ii) determine if the AII-induced proinflammatory mRNA responses depend on ambient glucose, and (iii) test the anti-inflammatory effectiveness of an ARB, valsartan, either alone or in combination with a statin, simvastatin. Valsartan 271-280 angiotensinogen Homo sapiens 139-142 19225232-9 2009 Valsartan blocked the AII-induced mRNA expression of proinflammatory genes (i.e. MCP-1, LIF and COX-2) maintained in normal and high glucose. Valsartan 0-9 angiotensinogen Homo sapiens 22-25 20502651-1 2010 An efficient synthesis of the angiotensin-II inhibitor valsartan (Diovan ) is presented. Valsartan 55-64 angiotensinogen Homo sapiens 30-44 20502651-1 2010 An efficient synthesis of the angiotensin-II inhibitor valsartan (Diovan ) is presented. Valsartan 66-72 angiotensinogen Homo sapiens 30-44 19911855-1 2009 Valsartan is a nonpeptide angiotensin receptor antagonist that selectively blocks the binding of angiotensin II to the angiotensin II type 1 receptor. Valsartan 0-9 angiotensinogen Homo sapiens 97-111 19911855-9 2009 Consistent with its angiotensin receptor-blocking effects, valsartan also reduces circulating levels of biochemical markers that are associated with angiotensin II-mediated endothelial dysfunction and CV risk (e.g. high-sensitivity C-reactive protein or oxidized low-density lipoprotein). Valsartan 59-68 angiotensinogen Homo sapiens 149-163 18633763-3 2008 In this study, we evaluated the long-term effect of the angiotensin II receptor blocker, valsartan, on IMT, arterial stiffness, and hemodynamics in the CCA in patients with essential hypertension. Valsartan 89-98 angiotensinogen Homo sapiens 56-70 17878892-10 2008 Co-incubation with increasing Ang II concentrations and valsartan indicated that Ang II effects were AT1-mediated. Valsartan 56-65 angiotensinogen Homo sapiens 81-87 18716376-5 2008 Pretreatment with valsartan, but not with PD123319, blocked angiotensin II-induced IP-10 mRNA expression. Valsartan 18-27 angiotensinogen Homo sapiens 60-74 18716376-6 2008 IP-10 levels in conditioned media detected by ELISA increased in response to angiotensin II compared to control, which was blocked by the pretreatment with valsartan. Valsartan 156-165 angiotensinogen Homo sapiens 77-91 18331727-13 2008 Benidipine partially inhibited angiotensin II-induced aldosterone production, plus showed additive effects when used in combination with the angiotensin II type I receptor blocker valsartan. Valsartan 180-189 angiotensinogen Homo sapiens 141-155 18207159-8 2008 Valsartan blockade of angiotensin II (angII)/angII type 1 receptor signaling prevented upregulation of RGS messages but only delayed mass increases, implying wall mass regulation involves both angII-dependent and angII-independent pathways. Valsartan 0-9 angiotensinogen Homo sapiens 22-36 18207159-8 2008 Valsartan blockade of angiotensin II (angII)/angII type 1 receptor signaling prevented upregulation of RGS messages but only delayed mass increases, implying wall mass regulation involves both angII-dependent and angII-independent pathways. Valsartan 0-9 angiotensinogen Homo sapiens 38-43 18207159-8 2008 Valsartan blockade of angiotensin II (angII)/angII type 1 receptor signaling prevented upregulation of RGS messages but only delayed mass increases, implying wall mass regulation involves both angII-dependent and angII-independent pathways. Valsartan 0-9 angiotensinogen Homo sapiens 45-50 18207159-8 2008 Valsartan blockade of angiotensin II (angII)/angII type 1 receptor signaling prevented upregulation of RGS messages but only delayed mass increases, implying wall mass regulation involves both angII-dependent and angII-independent pathways. Valsartan 0-9 angiotensinogen Homo sapiens 45-50 18207159-8 2008 Valsartan blockade of angiotensin II (angII)/angII type 1 receptor signaling prevented upregulation of RGS messages but only delayed mass increases, implying wall mass regulation involves both angII-dependent and angII-independent pathways. Valsartan 0-9 angiotensinogen Homo sapiens 45-50 17878892-12 2008 Valsartan alone slightly inhibited basal proliferation indicating an autocrine/paracrine growth factor-like effect of endogenous, adipocyte-derived Ang II. Valsartan 0-9 angiotensinogen Homo sapiens 148-154 17964282-3 2007 Valsartan, a selective Ang II type 1 (AT1) receptor blocker, and N-acetylcysteine, an antioxidant, inhibited both of these modifications, indicating the contribution of AT1 receptor and reactive oxygen species to oxidation of Prx2 and phosphorylation of GRP58 by Ang II. Valsartan 0-9 angiotensinogen Homo sapiens 23-29 17785354-10 2007 The specific AT(1) receptor blocker, valsartan, eliminated the effect of AII on adipocyte apoE expression. Valsartan 37-46 angiotensinogen Homo sapiens 73-76 17875818-9 2007 Finally, ATRAP knockdown by small-interference RNA activated angiotensin II-induced c-fos gene expression, which was effectively inhibited by valsartan, an AT1R-specific antagonist. Valsartan 142-151 angiotensinogen Homo sapiens 61-75 17715979-1 2007 An efficient synthesis of the angiotensin II inhibitor valsartan (Diovan) is presented. Valsartan 55-64 angiotensinogen Homo sapiens 30-44 17715979-1 2007 An efficient synthesis of the angiotensin II inhibitor valsartan (Diovan) is presented. Valsartan 66-72 angiotensinogen Homo sapiens 30-44 17702736-4 2007 RESULTS: Valsartan (320 mg) increased plasma renin activity and angiotensin I and angiotensin II levels, but 300 mg of aliskiren decreased them for 48 h. Aliskiren (300 mg) stimulated immunoreactive renin release more strongly than 320 mg of valsartan, decreased urinary aldosterone excretion for longer than 320 mg of valsartan, and had a similar BP-lowering effect as 320 mg of valsartan. Valsartan 9-18 angiotensinogen Homo sapiens 45-96